Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 17/11/2017
SIETES contiene 92128 citas

 
 
 1 a 20 de 683 siguiente >>
Presentar resultados
Seleccionar todas
2.Tiene citas relacionadas Cita con resumen
Poewe W, Seppi K. Insulin signalling: new target for Parkinson's treatments?. Lancet 2017;390:1628-30. [Ref.ID 102093]
3.Tiene citas relacionadas Cita con resumen
Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, Chowdhury K, Hibbert S, Budnik N, Zampedri L, Li Y, Avilés-Olmos I, Warner TT, Limousin P, Lees AJ, Greig NH, Tebbs S, Foltynie T. Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet 2017;390:1664-16875. [Ref.ID 102092]
4. Cita con resumen
Jhang KM, Huang J-Y, Nfor ON, Tung Y-C, Ku W-Y, Lee C-T, Liaw Y-P. Extrapyramidal symptoms after exposure to calcium channel blocker-flunarizine or cinnarizine. Eur J Clin Pharmacol 2017;73:911-6. [Ref.ID 101996]
5. Cita con resumen
Lin H-L, Lin H-C, Tseng Y-F, Chen SC, Hsu C-Y. Risk of parkinsonism induced by flunarizine or cinnarizine: a population-based study. Eur J Clin Pharmacol 2017;73:365-71. [Ref.ID 101941]
6. Cita con resumen
Anónimo. Safinamide et maladie de Parkinson avec fluctuations motrices. Prescrire 2017;37:90-1. [Ref.ID 101438]
7. Cita con resumen
Chen HK, Kwong JC, Copes R, Tu K, Villeneuve PJ, van Donkelaar A, Hystad P, Martin RV, Murray BJ, Jessiman B, Wilton AS, Kopp A, Burnett RT. Living near major roads and the incidence of dementia, Parkinson's disease, and multiple sclerosis: a population-based cohort study. Lancet 2017;389:718-26. [Ref.ID 101409]
9. Cita con resumen
Anónimo. Various states approve recreational, medical marijuana use. DIA Daily 2016:7. [Ref.ID 100907]
10.Enlace a cita original
Renoux C, Dell'Aniello S, Khairy P, Marras C, Bugden S, Turin TC, Blais L, Tamim H, Evans C, Steele R, Dormuth C, Ernst P, the Canadian Network for Observational Drug Effect Studies (CNODES) investigators. Ventricular tachyarrhythmia and sudden cardiac death with domperidone use in Parkinson's disease. Br J Clin Pharmacol 2016;82:461-72. [Ref.ID 100688]
11. Cita con resumen
Welk B, McArthur E, Morrow SA, MacDonald P, Hayward J, Leung A, Lum A. Association between gadolinium contrast exposure and the risk of parkinsonism. JAMA 2016;316:96-8. [Ref.ID 100620]
12. Cita con resumen
Anónimo. Pimavanserin (Nuplazid) for Parkinson's disease psychosis. Med Lett Drugs Ther 2016;58:74-5. [Ref.ID 100456]
13.Enlace a cita original Cita con resumen
Anónimo. FDA approves first drug to treat hallucinations and delusions associated with Parkinson’s disease. FDA U.S. Food and Drug Administration 2016:29 de abril. [Ref.ID 100215]
14. Cita con resumen
Casassus B. France releases interim report on drug trial disaster. Lancet 2016;387:634-5. [Ref.ID 100049]
16. Cita con resumen
Anónimo. Droxidopa (Northera) for neurogenic orthostatic hypotension. Med Lett Drugs Ther 2015;57:92-3. [Ref.ID 99270]
17.Enlace a cita original Cita con resumen
Lang Y, Gong D, Fan Y. Calcium channel blocker use and risk of Parkinson's disease: a meta-analysis. Pharmacoepidemiol Drug Saf 2015;24:559-66. [Ref.ID 99175]
18.Tiene citas relacionadas
Campbell NL, Boustani MA. Adverse cognitive effects of medications: turning attention to reversibility. JAMA Intern Med 2015;175:408-9. [Ref.ID 98843]
19.Tiene citas relacionadas Cita con resumen
Gray SL, Anderson ML, Dublin S, Hanlon JT, Hubbard R, Walker R, Yu O, Krane PK, Larson EB. Cumulative use of strong anticholinergics and incident dementia. A prospective cohort study. JAMA Intern Med 2015;175:401-7. [Ref.ID 98842]
20. Cita con resumen
Moore TJ, Glenmullen J, Mattison DR. Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs. JAMA Intern Med 2014;174:1930-3. [Ref.ID 98401]
Seleccionar todas
 
 1 a 20 de 683 siguiente >>